Daily Medication Pearl: Anifrolumab-fnia (Saphnelo)


Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody indicated for the treatment of moderate to severe systemic lupus erythematosus.

Medication Pearl of the Day: Anifrolumab-fnia (Saphnelo)

Indication: Saphnelo is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus, who are receiving standard therapy.


  • Dosing: The recommended dosage is 300 mg as an intravenous infusion over a 30-minute period every 4 weeks.
  • Dosage forms: Injection 300 mg/2 mL (150 mg/mL) in a single-dose vial.
  • Adverse events: Most common adverse drug reactions (incidence ≥5%) are nasopharyngitis, upper respiratory tract infections, bronchitis, infusion-related reactions, herpes zoster, and cough.
  • Mechanism of action: Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs.
  • Manufacturer: AstraZeneca


Saphnelo full Prescribing Information (den8dhaj6zs0e.cloudfront.net)

saphnelo image - Google Search

Related Videos
Female Pharmacist Holding Tablet PC - Image credit: Tyler Olson | stock.adobe.com
African American male pharmacist using digital tablet during inventory in pharmacy - Image credit: sofiko14 | stock.adobe.com
Young woman using smart phone,Social media concept. - Image credit: Urupong | stock.adobe.com
selling mental health medication to man at pharmacy | Image Credit: Syda Productions - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Image credit: rawpixel.com | stock.adobe.com
Medical team -- Image credit: Flamingo Images | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.